Insights into gemcitabine resistance and the potential for therapeutic monitoring.

ABSTRACT:

Introduction

Gemcitabine is an important component of pancreatic cancer clinical management. Unfortunately, acquired gemcitabine resistance is widespread and there are limitations to predicting and monitoring therapeutic outcomes.

Objective

To investigate the potential of metabolomics to differentiate pancreatic cancer cells that develops resistance or respond to gemcitabine treatment.

Results

We applied 1D ¹H and 2D ¹H-¹³C HSQC NMR methods to profile the metabolic signature of pancreatic cancer cells. ¹³C₆-glucose labeling identified 30 key metabolites uniquely altered between wild-type and gemcitabine-resistant cells upon gemcitabine treatment. Gemcitabine resistance was observed to reprogram glucose metabolism

SUBMITTER: Gebregiworgis T 

PROVIDER: S-EPMC6620022 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature